Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 3S-12S

  Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; OXACILLIN; PIPERACILLIN; TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; BACTERIAL INFECTION; BACTERIUM; CROSS INFECTION; DRUG ANTAGONISM; DRUG EFFECT; MICROBIOLOGY; PATHOGENICITY; PREVALENCE; REVIEW; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; PREVALENCE; UNITED STATES;

EID: 0030600071     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00102-7     Document Type: Conference Paper

References (53)

1. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993;6:428-442.
2. Advanced Report of Final Mortality Statistics. V 42. National Center for Health Statistics, 1992.
3. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991;(suppl 3B):72S-75S.
4. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, and the Fluoroquinolone Resistance Surveillance Group. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistance: real or perceived? Diagn Microbiol Infect Dis. 1994;19:203-215.
5. Gaynes RP, Culver DH, Emori TG, et al. The National Nosocomial Infections Surveillance System: plans for the 1990s and beyond. Am J Med. 1991;91(suppl 3B):116S-120S.
6. Hamory BH, Parisi JT. Staphylococcus epidermidis: a significant nosocomial pathogen. Am J Infect Control. 1987;15:59-74.
7. Stillman RI, Wenzel RP, Donowitz LC. Emergence of coagulase negative staphylococci as major nosocomial bloodstream pathogens. Infect Control. 1987;8:108-112.
8. Wenzel RP, Nettleman MD, Jones RN, Pfaller MA. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med. 1991;91(suppl 3B):221S-227S.
9. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987;316:927-931.
10. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993;37:1563-1571.
11. Centers for Disease Control. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR. 1993;42:597-599.
12. Jones RN, Sader HS, Erwin ME, Anderson SC, and the Enterococcus Study Group. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis. 1995;21:85-93.
13. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ, and the Pneumococcal Surveillance Working Group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis. 1991;163:1273-1278.
14. Thornsberry C, Marier JK, Rich TJ. Increased penicillin (pen) resistance in recent US isolates of Streptococcus pneumoniae. (Abstr. no. C-268.) In: Abstracts of the 92nd General Meeting of the American Society for Microbiology 1992 (New Orleans). Washington, DC: American Society for Microbiology, 1992:465.
15. Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 1995;9:497-530.
16. Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994;13(suppl 1):17-29.
17. Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA, Bush K. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrob Agents Chemother. 1994;38:761-766.
18. Sader HS, Pfaller MA, Jones RN. Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of intra- and interlaboratory dissemination of extended-spectrum β-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 1994;20:203-208.
19. Burwen DR, Banerjee SN, Gaynes RP, and the National Nosocomial Infections Surveillance System. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis. 1994;170:1622-1625.
20. Bush K. Classification of β-lactamases: groups 1, 2a, 2b, and 2b′. Antimicrob Agents Chemother. 1989;33:264-270.
21. Thornsberry C, Brown SD, Yee YC, et al. In vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother. 1993;32(suppl B):31-53.
22. Sanders CC. β-Lactamases of gram-negative bacteria: new challenges for new drugs. Clin Infect Dis. 1992;14:1089-1099.
23. Sanders WE Jr, Sanders CC. Inducible β-lactamases: clinical and epidemiological implications for use of newer cephalosporins. Rev Infect Dis. 1988;10:830-838.
24. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-590.
25. Murray PR, Cantrell HF, Lankford RB, and the In Vitro Susceptibility Surveillance Group. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected β-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. Diagn Microbiol Infect Dis. 1994;19:111-120.
26. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group I β-lactamase-producing strains resistant to ceftazidime: a multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis. 1994;19:33-38.
27. Sader HS, Jones RN. In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies. Eur J Clin Microbiol Infect Dis. 1994;13:675-679.
28. Sanchez ML, Jones RN. Antimicrobial activity of FK-037 against class I β-lactamase producing species resistant to ceftazidime: a multilaboratory clinical isolate sample. J Antimicrob Chemother. 1993;32:654-656.
29. Marshall SA, Aldridge KE, Allen SD, et al. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers: a reevaluation after five years. Diagn Microbiol Infect Dis. 1995;21:153-168.
30. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med. 1991;324:601-612.
31. Stratton CW, Ratner H, Johnston PE, Schaffner W. Focused microbiologic surveillance by specific hospital unit as a sensitive means of defining antimicrobial resistance problems. Diagn Microbiol Infect Dis. 1992;15: 11S-18S.
32. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991;35:147-151.
33. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990;34:52-57.
34. Fung-Tomc J, Kolek B, Bonner DP. Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1993;37:1289-1296.
35. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis. 1992;15:37S-42S.
36. Lewis R. The rise of antibiotic-resistant infections. FDA Consumer. 1995;29:11-15.
37. Toye BW, Scriver SR, Low DE, and the Canadian Antimicrobial Resistance Study Group. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother. 1993;32(suppl B):81-86.
38. Yee YC, Thornsberry C, Brown SD, Bouchillon SK, Marler JK, Rich T. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1993;32(suppl B):13-19.
39. McCabe R, Chirurgi V, Farkas SA, et al. A new therapeutic option for the treatment of pneumonia. Am J Med. 1996;100(suppl 6A):60S-67S.
40. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother. 1994;38:898-900.
41. Stratton CW, Aldridge KE, Gelfand MS. In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus penumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagn Microbiol Infect Dis. 1995;22:35-42.
42. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol. 1992;13:582-586.
43. Thomson KS, Sanders WE, Sanders CC. USA resistance patterns among UTI pathogens. J Antimicrob Chemother. 1994;33(suppl A):9-15.
44. Sanders CC. Cefepime: the next generation? Clin Infect Dis. 1993; 17:369-379.
45. Jones RN. Review of the in vitro spectrum of activity of imipenem. Am J Med. 1985;78(suppl A):22-32.
46. Jones RN, Barry AL, Thornsberry C. In vitro studies of meropenem. J Antimicrob Chemother. 1989;24(suppl A):9-29.
47. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs. 1996;51:99-136.
48. Kessler RE, Bies M, Buck RE, et al. Comparison of a new cephalosporin, BMY-28142, with other broad-spectrum β-lactam antibiotics. Antimicrob Agents Chemother. 1985:27:207-216.
49. Schwartz R, Das Young LR, Ramirez-Ronda C, Frank E. Current and future management of serious skin and skin-structure infections. Am J Med. 1996;100(suppl 6A):90S-95S.
50. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47: 471-505.
51. Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother. 1993;32:(suppl B):75-80.
52. Sharifi R, Geckler R, Childs S. Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infection. Am J Med. 1996;100(suppl 6A):76S-82S.
53. Gouin F, Papazian L, Martin C, et al. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother. 1993;32(suppl B):205-214.